Related Experiment Video

Updated: Jun 18, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Targeted degradation of CBP/p300 by CBPD-409 exhibits robust anti-myeloma activity

S Corradini1, M Maksimos2, F Azab2

  • 1Research Centre for Health, School of Health and Life Sciences, Department of Biological and Biomedical Sciences, Glasgow Caledonian University, Glasgow, UK.

Leukemia
|June 16, 2026
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

Related Experiment Videos

Last Updated: Jun 18, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity
11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Articles linked to this work by shared authors, journal, and citation graph.

Discovery of Highly Efficacious CRBN-Based KRAS Degraders Targeting Cancers with KRAS G12D and G12V Mutations.

Journal of medicinal chemistry·2026

A Direct-to-Biology Amine-Acid Amination for Rapid Phenotypic Profiling of Lysosomotropic Natural Products.

Journal of the American Chemical Society·2026

When Myeloma Escapes the Bone Marrow: Extramedullary Disease in the Immunotherapy Era.

Cancers·2026

Discovery of SD-2301 as a Highly Potent and Selective PROTAC STAT3 Degrader Capable of Achieving Complete Tumor Regression with Single Administration.

Journal of medicinal chemistry·2026

Discovery of SMD-6346: A Potent, Selective, and Orally Active SMARCA2 Degrader for Targeting SMARCA4-Deficient Human Cancers.

Journal of medicinal chemistry·2026

Dental Educators' Perceptions of Factors Contributing to Their Well-being-A Qualitative Study.

European journal of dental education : official journal of the Association for Dental Education in Europe·2026

Serine auxotrophy is a targetable vulnerability driven by PSAT1 suppression in AML.

Leukemia·2026

Predicting long-term survival in primary myelofibrosis.

Leukemia·2026

Targeting the mitochondrial complex I subunit NDUFS2 potentiates FLT3 inhibition in acute myeloid leukaemia with FLT3 internal tandem duplication.

Leukemia·2026

Targeting the eIF4F translation initiation complex disrupts BCR::ABL1 translation and overcomes drug resistance in CML.

Leukemia·2026

Neoantigenic receptor ROR1 promotes cell growth through diverse and complementary mechanisms.

Leukemia·2026

Inhibition of PHB2/PINK1-mediated mitophagy potentiates venetoclax activity in acute myeloid leukemia.

Leukemia·2026

Long-term Glycemia and Risk of Death in Cystic Fibrosis-Related Diabetes: A UK Cystic Fibrosis Registry Study.

Diabetes care·2026

Association of Ultrafiltration Rate with Structural Remodeling of the Left Heart and Arrhythmias in Hemodialysis Patients: A Cross-Sectional Observational Study.

Clinics and practice·2026

Psychometric Evaluation of the Serbian MacNew Heart Disease Health-Related Quality of Life Questionnaire Before and After Elective Coronary Artery Bypass Grafting.

Epidemiologia (Basel, Switzerland)·2026

Depression, C-Reactive Protein, and the Risk of Mortality During Middle and Late Adulthood.

Epidemiologia (Basel, Switzerland)·2026

Temporal Distribution of Elevated-HbA1c Records and a Young-Adult Multiorgan Biomarker Profile in Diabetes: A Retrospective Observational Study.

Diseases (Basel, Switzerland)·2026

Temporal Dynamics of Emerging Cardiovascular Biomarkers in the Early Phase After Acute ST-Segment Elevation Myocardial Infarction: A Prospective Single-Center Pilot Study.

Cells·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us